A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal Impairment - Trial NCT05673603
Access comprehensive clinical trial information for NCT05673603 through Pure Global AI's free database. This Phase 1 trial is sponsored by Insmed Incorporated and is currently Completed. The study focuses on Renal Impairment. Target enrollment is 28 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Insmed Incorporated
Timeline & Enrollment
Phase 1
Jul 20, 2021
Feb 14, 2023
Primary Outcome
Area Under the Plasma Concentration Time Curve (AUC) of Brensocatib,Maximum Observed Plasma Concentration (Cmax) of Brensocatib,Time to Reach Maximum Observed Plasma Concentration (Tmax) of Brensocatib,Number of Participants who Experienced at Least one Adverse Event (AE)
Summary
The primary purpose of the study is to determine the pharmacokinetics (PK) following a single
 oral dose administration of brensocatib, safety, and tolerability of brensocatib when
 administered to participants with impaired renal function and in healthy participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05673603
Non-Device Trial